"Adamantane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricyclo bridged hydrocarbon.
| Descriptor ID |
D000218
|
| MeSH Number(s) |
D02.455.426.100.050 D02.455.426.392.368.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adamantane".
Below are MeSH descriptors whose meaning is more specific than "Adamantane".
This graph shows the total number of publications written about "Adamantane" by people in this website by year, and whether "Adamantane" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 10 | 6 | 16 |
| 2018 | 2 | 3 | 5 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adamantane" by people in Profiles.
-
Potential for the Repurposing of Adamantane Antivirals for COVID-19. Drugs R D. 2021 Sep; 21(3):267-272.
-
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem. 2021 05 06; 16(9):1425-1426.
-
Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels. ACS Chem Biol. 2020 09 18; 15(9):2331-2337.
-
A retrospective review of memantine use and COVID-19-associated mortality from a national database. J Med Virol. 2021 01; 93(1):168-169.
-
The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol. 2020 11; 92(11):2341-2342.
-
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 Jul; 42:102163.
-
Potentially repurposing adamantanes for COVID-19. J Med Virol. 2020 06; 92(6):531-532.
-
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 11 05; 140(19):1569-1577.
-
The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-?B. Eur J Pharmacol. 2019 May 15; 851:186-193.
-
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. Rev Assoc Med Bras (1992). 2019 Jan; 65(1):33-37.